Resmetirom

Phase 3

Madrigal Pharmaceuticals, Inc. (MDGL)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

MDGLPhase 3$11.8B

Resmetirom Phase 3 Est. Readout

Resmetirom• NASH845

Dec 2026~ConfirmedSTALE

CT.gov

00%

Dec '26

MDGLPhase 2$11.8B

Resmetirom Phase 2 Est. Readout

Resmetirom• NASH120

Dec 2026~ConfirmedSTALE

CT.gov

00%

Competitive Landscape

1 competitor in NASH

View Full Landscape

Drug Information

Target Indication

NASH

Clinical Trial

NCT05500222

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA8/18/2025

Rezdiffra

Rezdiffra is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (fibrosis stages F2 to F3).

Conditional

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

MDGL

Madrigal Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

MGL-3196Phase 3

Heterozygous Familial Hypercholesterolemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts